Global Influenza Diagnostics research
Global Influenza Diagnostics research

Influenza Diagnostics Comprehensive Study by Type (Rapid Influenza Diagnostic Tests (RIDT), Direct Fluorescent Antibody (DFA) Tests, Molecular Diagnostic Tests, Traditional Diagnostic Tests, Viral Culture, Others), Application (Hospitals & Clinics, Research Laboratories, Other) Players and Region - Global Market Outlook to 2024

Influenza Diagnostics Market Segmented into XX Submarkets. | Forecast Years: 2019- 2024 | CAGR: 6.86%  

Nov 2019 Edition 201 Pages 221 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Influenza Diagnostics Market Overview:
Influenza diagnostics is critical for clinical management that enables medical professionals to quickly determine if a patient has the flu and if so. Accurate diagnose of influenza is infection control and public health actions to minimize the burden of influenza. Influenza testing detects the presence of the virus in a sample of respiratory secretions. The rapidly growing demand for point-of-care diagnostic is the major driving factor in the influenza diagnostics market growth globally. Moreover, the recent influenza outbreaks have prompted healthcare authorities to increase the capacity of influenza diagnosis globally. Some of the key players profiled in the study are Alere Inc. (United States), Abbott Laboratories (United States), bioMérieux SA (France), Thermo Fisher Scientific (United States), Roche Diagnostics (Switzerland), Bio-Rad Laboratories Inc. (United States), Quidel Corporation (United States), Becton, Dickinson and Company (United States), DiaSorin (Italy), A Scientific (United States) and Luminex Corporation (United States). According to Market Analyst at AMA, the Global Influenza Diagnostics market may see a growth rate of 6.86% and would reach the market size of USD923.14 Million by 2024.

On the basis of geography, the market of Influenza Diagnostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Drivers
  • Increasing Prevalence of Influenza across the World
  • Growth in Research Funding for Influenza Diagnostics, Mostly in Developed Nations
  • Growing Demand for Faster Diagnosis and Control of Influenza Globally

Market Trend
  • Advancements in Genomic and Proteomic Technologies

Restraints
  • Rising Demand for Early Diagnosis and Control of Influenza
  • Increasing Healthcare Costs Limiting the Usage of Novel Influenza Diagnostic Techniques

Opportunities
  • The Growth in the Number of Approvals of Influenza Diagnostic Products by Regulatory Authorities

Challenges
  • Stringent Regulatory Framework
  • The Dearth of Skilled Personnel to Handle Advanced Influenza Diagnostic Tools in Developing Nations



The FDA convened an advisory panel in June 2013 to discuss options to improve the regulation of the performance of RIDTs. A proposed order was published on 22 May 2014, and the final order published on 12 January 2017, reclassifying RIDTs from class I to class II medical devices, with additional requirements to comply with four new special controls.

Target Audience:
Doctors, Physicians, Academic Institutes, Diagnostic Solution Providers, Research Institutes, Reference Laboratories, Diagnostic Suppliers, Home Health Agencies, Market Research and Consulting Firms and Others

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Influenza Diagnostics market on the basis of product [Rapid Influenza Diagnostic Tests (RIDT), Direct Fluorescent Antibody (DFA) Tests, Molecular Diagnostic Tests, Traditional Diagnostic Tests, Viral Culture and Others] , application [Hospitals & Clinics, Research Laboratories and Other], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Influenza Diagnostics market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Influenza Diagnostics industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are Meridian Bioscience, Inc. (United States), Princeton BioMedtech corp. (United States) and Sekisui Medical Co., Ltd. (Japan).
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Influenza Diagnostics market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. Top-down and bottom-up approaches have been used to determine the overall market size. Sizes of the other individual markets have been estimated using the percentage splits obtained through secondary sources such as Hoovers, Bloomberg BusinessWeek, and Dow Jones (Factiva), along with primary respondents. The complete methodology includes the study of the annual and financial reports of the key market players and extensive interviews with industry experts such as CEOs, VPs, directors, and marketing executives for key insights (both qualitative and quantitative) related to the market.
Report Objectives / Segmentation Covered
By Type
  • Rapid Influenza Diagnostic Tests (RIDT)
  • Direct Fluorescent Antibody (DFA) Tests
  • Molecular Diagnostic Tests
  • Traditional Diagnostic Tests
  • Viral Culture
  • Others
By Application
  • Hospitals & Clinics
  • Research Laboratories
  • Other
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Influenza across the World
      • 3.2.2. Growth in Research Funding for Influenza Diagnostics, Mostly in Developed Nations
      • 3.2.3. Growing Demand for Faster Diagnosis and Control of Influenza Globally
    • 3.3. Market Challenges
      • 3.3.1. Stringent Regulatory Framework
      • 3.3.2. The Dearth of Skilled Personnel to Handle Advanced Influenza Diagnostic Tools in Developing Nations
    • 3.4. Market Trends
      • 3.4.1. Advancements in Genomic and Proteomic Technologies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Influenza Diagnostics, by Type, Application and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Influenza Diagnostics (Value)
      • 5.2.1. Global Influenza Diagnostics by: Type (Value)
        • 5.2.1.1. Rapid Influenza Diagnostic Tests (RIDT)
        • 5.2.1.2. Direct Fluorescent Antibody (DFA) Tests
        • 5.2.1.3. Molecular Diagnostic Tests
        • 5.2.1.4. Traditional Diagnostic Tests
        • 5.2.1.5. Viral Culture
        • 5.2.1.6. Others
      • 5.2.2. Global Influenza Diagnostics by: Application (Value)
        • 5.2.2.1. Hospitals & Clinics
        • 5.2.2.2. Research Laboratories
        • 5.2.2.3. Other
      • 5.2.3. Global Influenza Diagnostics Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Influenza Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Alere Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BioMérieux SA (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Thermo Fisher Scientific (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Roche Diagnostics (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bio-Rad Laboratories Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Quidel Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Becton, Dickinson and Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. DiaSorin (Italy)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. A Scientific (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Luminex Corporation (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Influenza Diagnostics Sale, by Type, Application and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Influenza Diagnostics (Value)
      • 7.2.1. Global Influenza Diagnostics by: Type (Value)
        • 7.2.1.1. Rapid Influenza Diagnostic Tests (RIDT)
        • 7.2.1.2. Direct Fluorescent Antibody (DFA) Tests
        • 7.2.1.3. Molecular Diagnostic Tests
        • 7.2.1.4. Traditional Diagnostic Tests
        • 7.2.1.5. Viral Culture
        • 7.2.1.6. Others
      • 7.2.2. Global Influenza Diagnostics by: Application (Value)
        • 7.2.2.1. Hospitals & Clinics
        • 7.2.2.2. Research Laboratories
        • 7.2.2.3. Other
      • 7.2.3. Global Influenza Diagnostics Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Influenza Diagnostics: by Type(USD Million)
  • Table 2. Influenza Diagnostics Rapid Influenza Diagnostic Tests (RIDT) , by Region USD Million (2013-2018)
  • Table 3. Influenza Diagnostics Direct Fluorescent Antibody (DFA) Tests , by Region USD Million (2013-2018)
  • Table 4. Influenza Diagnostics Molecular Diagnostic Tests , by Region USD Million (2013-2018)
  • Table 5. Influenza Diagnostics Traditional Diagnostic Tests , by Region USD Million (2013-2018)
  • Table 6. Influenza Diagnostics Viral Culture , by Region USD Million (2013-2018)
  • Table 7. Influenza Diagnostics Others , by Region USD Million (2013-2018)
  • Table 8. Influenza Diagnostics: by Application(USD Million)
  • Table 9. Influenza Diagnostics Hospitals & Clinics , by Region USD Million (2013-2018)
  • Table 10. Influenza Diagnostics Research Laboratories , by Region USD Million (2013-2018)
  • Table 11. Influenza Diagnostics Other , by Region USD Million (2013-2018)
  • Table 12. South America Influenza Diagnostics, by Country USD Million (2013-2018)
  • Table 13. South America Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 14. South America Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 15. Brazil Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 16. Brazil Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 17. Argentina Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 18. Argentina Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 19. Rest of South America Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 20. Rest of South America Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 21. Asia Pacific Influenza Diagnostics, by Country USD Million (2013-2018)
  • Table 22. Asia Pacific Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 23. Asia Pacific Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 24. China Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 25. China Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 26. Japan Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 27. Japan Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 28. India Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 29. India Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 30. South Korea Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 31. South Korea Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 32. Taiwan Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 33. Taiwan Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 34. Australia Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 35. Australia Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 36. Rest of Asia-Pacific Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 37. Rest of Asia-Pacific Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 38. Europe Influenza Diagnostics, by Country USD Million (2013-2018)
  • Table 39. Europe Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 40. Europe Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 41. Germany Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 42. Germany Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 43. France Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 44. France Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 45. Italy Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 46. Italy Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 47. United Kingdom Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 48. United Kingdom Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 49. Netherlands Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 50. Netherlands Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 51. Rest of Europe Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 52. Rest of Europe Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 53. MEA Influenza Diagnostics, by Country USD Million (2013-2018)
  • Table 54. MEA Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 55. MEA Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 56. Middle East Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 57. Middle East Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 58. Africa Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 59. Africa Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 60. North America Influenza Diagnostics, by Country USD Million (2013-2018)
  • Table 61. North America Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 62. North America Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 63. United States Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 64. United States Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 65. Canada Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 66. Canada Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 67. Mexico Influenza Diagnostics, by Type USD Million (2013-2018)
  • Table 68. Mexico Influenza Diagnostics, by Application USD Million (2013-2018)
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Influenza Diagnostics: by Type(USD Million)
  • Table 81. Influenza Diagnostics Rapid Influenza Diagnostic Tests (RIDT) , by Region USD Million (2019-2024)
  • Table 82. Influenza Diagnostics Direct Fluorescent Antibody (DFA) Tests , by Region USD Million (2019-2024)
  • Table 83. Influenza Diagnostics Molecular Diagnostic Tests , by Region USD Million (2019-2024)
  • Table 84. Influenza Diagnostics Traditional Diagnostic Tests , by Region USD Million (2019-2024)
  • Table 85. Influenza Diagnostics Viral Culture , by Region USD Million (2019-2024)
  • Table 86. Influenza Diagnostics Others , by Region USD Million (2019-2024)
  • Table 87. Influenza Diagnostics: by Application(USD Million)
  • Table 88. Influenza Diagnostics Hospitals & Clinics , by Region USD Million (2019-2024)
  • Table 89. Influenza Diagnostics Research Laboratories , by Region USD Million (2019-2024)
  • Table 90. Influenza Diagnostics Other , by Region USD Million (2019-2024)
  • Table 91. South America Influenza Diagnostics, by Country USD Million (2019-2024)
  • Table 92. South America Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 93. South America Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 94. Brazil Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 95. Brazil Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 96. Argentina Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 97. Argentina Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 98. Rest of South America Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 99. Rest of South America Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 100. Asia Pacific Influenza Diagnostics, by Country USD Million (2019-2024)
  • Table 101. Asia Pacific Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 102. Asia Pacific Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 103. China Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 104. China Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 105. Japan Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 106. Japan Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 107. India Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 108. India Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 109. South Korea Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 110. South Korea Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 111. Taiwan Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 112. Taiwan Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 113. Australia Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 114. Australia Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 115. Rest of Asia-Pacific Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 116. Rest of Asia-Pacific Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 117. Europe Influenza Diagnostics, by Country USD Million (2019-2024)
  • Table 118. Europe Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 119. Europe Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 120. Germany Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 121. Germany Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 122. France Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 123. France Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 124. Italy Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 125. Italy Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 126. United Kingdom Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 127. United Kingdom Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 128. Netherlands Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 129. Netherlands Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 130. Rest of Europe Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 131. Rest of Europe Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 132. MEA Influenza Diagnostics, by Country USD Million (2019-2024)
  • Table 133. MEA Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 134. MEA Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 135. Middle East Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 136. Middle East Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 137. Africa Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 138. Africa Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 139. North America Influenza Diagnostics, by Country USD Million (2019-2024)
  • Table 140. North America Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 141. North America Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 142. United States Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 143. United States Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 144. Canada Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 145. Canada Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 146. Mexico Influenza Diagnostics, by Type USD Million (2019-2024)
  • Table 147. Mexico Influenza Diagnostics, by Application USD Million (2019-2024)
  • Table 148. Research Programs/Design for This Report
  • Table 149. Key Data Information from Secondary Sources
  • Table 150. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Influenza Diagnostics: by Type USD Million (2013-2018)
  • Figure 5. Global Influenza Diagnostics: by Application USD Million (2013-2018)
  • Figure 6. South America Influenza Diagnostics Share (%), by Country
  • Figure 7. Asia Pacific Influenza Diagnostics Share (%), by Country
  • Figure 8. Europe Influenza Diagnostics Share (%), by Country
  • Figure 9. MEA Influenza Diagnostics Share (%), by Country
  • Figure 10. North America Influenza Diagnostics Share (%), by Country
  • Figure 11. Global Influenza Diagnostics share by Players 2018 (%)
  • Figure 12. Global Influenza Diagnostics share by Players (Top 3) 2018(%)
  • Figure 13. Global Influenza Diagnostics share by Players (Top 5) 2018(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Alere Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 16. Alere Inc. (United States) Revenue: by Geography 2018
  • Figure 17. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott Laboratories (United States) Revenue: by Geography 2018
  • Figure 19. BioMérieux SA (France) Revenue, Net Income and Gross profit
  • Figure 20. BioMérieux SA (France) Revenue: by Geography 2018
  • Figure 21. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 22. Thermo Fisher Scientific (United States) Revenue: by Geography 2018
  • Figure 23. Roche Diagnostics (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Roche Diagnostics (Switzerland) Revenue: by Geography 2018
  • Figure 25. Bio-Rad Laboratories Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Bio-Rad Laboratories Inc. (United States) Revenue: by Geography 2018
  • Figure 27. Quidel Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 28. Quidel Corporation (United States) Revenue: by Geography 2018
  • Figure 29. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 30. Becton, Dickinson and Company (United States) Revenue: by Geography 2018
  • Figure 31. DiaSorin (Italy) Revenue, Net Income and Gross profit
  • Figure 32. DiaSorin (Italy) Revenue: by Geography 2018
  • Figure 33. A Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 34. A Scientific (United States) Revenue: by Geography 2018
  • Figure 35. Luminex Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 36. Luminex Corporation (United States) Revenue: by Geography 2018
  • Figure 37. Global Influenza Diagnostics: by Type USD Million (2019-2024)
  • Figure 38. Global Influenza Diagnostics: by Application USD Million (2019-2024)
  • Figure 39. South America Influenza Diagnostics Share (%), by Country
  • Figure 40. Asia Pacific Influenza Diagnostics Share (%), by Country
  • Figure 41. Europe Influenza Diagnostics Share (%), by Country
  • Figure 42. MEA Influenza Diagnostics Share (%), by Country
  • Figure 43. North America Influenza Diagnostics Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Alere Inc. (United States)
  • Abbott Laboratories (United States)
  • bioMérieux SA (France)
  • Thermo Fisher Scientific (United States)
  • Roche Diagnostics (Switzerland)
  • Bio-Rad Laboratories Inc. (United States)
  • Quidel Corporation (United States)
  • Becton, Dickinson and Company (United States)
  • DiaSorin (Italy)
  • A Scientific (United States)
  • Luminex Corporation (United States)
Additional players considered in the study are as follows:
Meridian Bioscience, Inc. (United States) , Princeton BioMedtech corp. (United States) , Sekisui Medical Co., Ltd. (Japan)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation